Patients receiving the recommended dose of 1200 mg in the phase II study yielded an ORR of 37% in ICI-naïve PD-L1–positive tumors (response in 10 of 27 patients) and 85.7% (response in 6 of 7) in subjects with high-PD-L1 tumor expression. This evidence concerns the gene CD274 and neoplasm.